106 related articles for article (PubMed ID: 25441945)
61. Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans.
Wagner R; Hieronimus A; Lamprinou A; Heni M; Hatziagelaki E; Ullrich S; Stefan N; Staiger H; Häring HU; Fritsche A
Mol Metab; 2014 Sep; 3(6):676-80. PubMed ID: 25161890
[TBL] [Abstract][Full Text] [Related]
62. Variants in the FFAR1 gene are associated with beta cell function.
Kalis M; Levéen P; Lyssenko V; Almgren P; Groop L; Cilio CM
PLoS One; 2007 Nov; 2(11):e1090. PubMed ID: 17987108
[TBL] [Abstract][Full Text] [Related]
63. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.
Zhou C; Tang C; Chang E; Ge M; Lin S; Cline E; Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger J; Howard AD; Thornberry N; Mills SG; Yang L
Bioorg Med Chem Lett; 2010 Feb; 20(3):1298-301. PubMed ID: 20064714
[TBL] [Abstract][Full Text] [Related]
64. Exploration of LPS
Chen L; Uwamizu A; Sayama M; Kano K; Otani Y; Kondo S; Inoue A; Aoki J; Ohwada T
Eur J Med Chem; 2023 Apr; 252():115271. PubMed ID: 36965226
[TBL] [Abstract][Full Text] [Related]
65. For Better or Worse: FFAR1 and FFAR4 Signaling in Cancer and Diabetes.
Houthuijzen JM
Mol Pharmacol; 2016 Dec; 90(6):738-743. PubMed ID: 27582526
[TBL] [Abstract][Full Text] [Related]
66. [Possible involvement of FFAR1 signaling in mouse emotional behaviors through the regulation of brain monoamine releases].
Kurihara T
Nihon Yakurigaku Zasshi; 2023; 158(6):454-459. PubMed ID: 37914322
[TBL] [Abstract][Full Text] [Related]
67. Structural basis for GPCR signaling by small polar versus large lipid metabolites-discovery of non-metabolite ligands.
Lückmann M; Trauelsen M; Frimurer TM; Schwartz TW
Curr Opin Cell Biol; 2020 Apr; 63():38-48. PubMed ID: 31951921
[TBL] [Abstract][Full Text] [Related]
68. The impact of water molecules on binding affinity of the anti-diabetic thiazolidinediones for catalase: Kinetic and mechanistic approaches.
Yekta R; Dehghan G; Rashtbari S; Sadeghi L; Baradaran B; Sheibani N; Moosavi-Movahedi AA
Arch Biochem Biophys; 2019 Mar; 664():110-116. PubMed ID: 30738039
[TBL] [Abstract][Full Text] [Related]
69. Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis.
Tsakovska I; Al Sharif M; Alov P; Diukendjieva A; Fioravanzo E; Cronin MT; Pajeva I
Int J Mol Sci; 2014 May; 15(5):7651-66. PubMed ID: 24857909
[TBL] [Abstract][Full Text] [Related]
70. [The possibility of a novel pain control system through brain long chain fatty acid receptor GPR40/FFAR1].
Nakamoto K; Tokuyama S
Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):302-8. PubMed ID: 26657120
[No Abstract] [Full Text] [Related]
71. Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.
Geldenhuys WJ; Funk MO; Barnes KF; Carroll RT
Bioorg Med Chem Lett; 2010 Feb; 20(3):819-23. PubMed ID: 20064719
[TBL] [Abstract][Full Text] [Related]
72. Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action.
Lückmann M; Shenol A; Nissen TAD; Petersen JE; Kouvchinov D; Schwartz TW; Frimurer TM
ACS Med Chem Lett; 2022 Dec; 13(12):1839-1847. PubMed ID: 36518697
[TBL] [Abstract][Full Text] [Related]
73. Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations.
An X; Bai Q; Bing Z; Liu H; Yao X
Comput Struct Biotechnol J; 2021; 19():3978-3989. PubMed ID: 34377364
[TBL] [Abstract][Full Text] [Related]
74. Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies.
Pon'kina DA; Kuranov SO; Marenina MK; Meshkova YV; Zhukova NA; Khvostov MV; Luzina OA; Tolstikova TG; Salakhutdinov NF
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376118
[TBL] [Abstract][Full Text] [Related]
75. Corrigendum: Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1.
Joyal JS; Sun Y; Gantner ML; Shao Z; Evans LP; Saba N; Fredrick T; Burnim S; Kim JS; Patel G; Juan AM; Hurst CG; Hatton CJ; Cui Z; Pierce KA; Bherer P; Aguilar E; Powner MB; Vevis K; Boisvert M; Fu Z; Levy E; Fruttiger M; Packard A; Rezende FA; Maranda B; Sapieha P; Chen J; Friedlander M; Clish CB; Smith LE
Nat Med; 2016 Jun; 22(6):692. PubMed ID: 27270778
[No Abstract] [Full Text] [Related]
76. Diabetes: FFAR1 activation improves glycemia.
Koch L
Nat Rev Endocrinol; 2012 Mar; 8(5):257. PubMed ID: 22411434
[No Abstract] [Full Text] [Related]
77. Computational studies to predict or explain G protein coupled receptor polypharmacology.
Jacobson KA; Costanzi S; Paoletta S
Trends Pharmacol Sci; 2014 Dec; 35(12):658-63. PubMed ID: 25458540
[TBL] [Abstract][Full Text] [Related]
78. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice.
Chen Y; Ren Q; Zhou Z; Deng L; Hu L; Zhang L; Li Z
Br J Pharmacol; 2020 May; 177(10):2286-2302. PubMed ID: 31971610
[TBL] [Abstract][Full Text] [Related]
79. Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation.
Helal MA; Darwish KM; Hammad MA
Bioorg Med Chem Lett; 2014 Nov; 24(22):5330-6. PubMed ID: 25441945
[TBL] [Abstract][Full Text] [Related]
80. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
